HIV / AIDS in the News

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Benzinga

 

GABARAP proteins regulate the packaging of HIV-1 genomic RNA into virions - EMBO Press

 

Man with HIV accused of raping children, spreading disease, officials confirm - WKYT

 

Man with HIV accused of raping children, spreading disease, officials confirm - KBTX News 3

 

Man with HIV accused of raping children, spreading disease, officials confirm - WLBT

 

Man with HIV accused of raping children, spreading disease, officials confirm - WIS News 10

 

Man with HIV accused of raping children, spreading disease, officials confirm - webcenterfairbanks.com

 

US Aid cuts are undermining Senegal’s fight against HIV - Thred

 

Gilead Stock Reverses; Why Its New HIV Shot Looks Better - Investor's Business Daily

 

Gilead's long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales - Fierce Pharma

 

Suspect accused of child rape, spreading HIV, arrested by Memphis Safe Task Force - Action News 5

 

Safe Task Force arrests child sex crime suspect with HIV - WREG.com

 

Improving tobacco cessation care for people living with HIV - News-Medical

 

Decision-making and acceptability of subcutaneously administered broadly neutralising monoclonal antibodies for HIV prevention amongst CAPRISA 012A trial participants in Durban, South Africa - Nature

 

GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow - Zacks Investment Research

 

GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds - Yahoo Finance

 

Children test positive for HIV after blood transfusions in India - The Independent

 

Alarm in India after children contract HIV from contaminated blood - The Independent

 

Gilead Sciences (NASDAQ: GILD) awarded 2025 Prix Galien USA for Yeztugo PrEP - Stock Titan

 

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir) - Yahoo Finance

 

Maldives Eliminates Mother-to-Child Transmission of HIV, Syphilis and Hepatitis B - Angels in Medicine

 

HOOKIPA Pharma (OTC: HOOK) closes sale of HB-400 and HB-500 program assets to Gilead - Stock Titan

 

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - Yahoo Finance

 

Gilead Still Hungry for Deals as HIV Portfolio Grows, Veklury Crashes - BioSpace

 

Gilead Sciences’ HIV Drug Sales Lead A Strong Quarter - Finimize

 

'Lack of interpreters meant I believed I had HIV for two days' - BBC

 

Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ... - Yahoo Finance

 

Are skilled nursing providers ready to care? - McKnight's Long-Term Care News

 

Gilead raises 2025 HIV revenue growth outlook to 5% as Biktarvy and Descovy drive momentum - MSN

 

Federal shutdown threatens healthcare access for people living with HIV in South Carolina - WLTX